New evidence on molecular mechanisms involved in psoriasis outset Blog Post

Two translational research studies published in the high impact scientific magazines Journal of Allergy and Clinical Immunology and Journal of Investigative Dermatology have described new immunologic mechanisms in psoriasis, a chronic cutaneous inflammatory disease which affects around the 2% of the population. The studies have been led by Lluís Francesc Santamaria, Director of the group of Translationary Immunology of the University of Barcelona (UB) based at the Barcelona Science Park, together with researchers of the Hospital del Mar and the Municipal Institute for Medical Research, among others.

 

IDP Pharma closes a funding round for 2 million euros Blog Post

IDP Pharma, founded in 2015 and with headquarters at the Barcelona Science Park (PCB) has raised, during its first operative year, over 2 million euros from public and private capital. The biopharmaceutical company –specializes in the development of drugs for cancer treatment directed to a new class of therapeutic targets: IDPs– will appoint this capital to continue the preclinical development of their most advanced products: two first-in-class molecules with antitumor activity for Multiple Myeloma, the second most common blood cancer

 

Mundipharma-Purdue reach a new deal to in-licence from Esteve full global rights for novel first-in-class AS1 for the management of pain Blog Post

Mundipharma its independent associated company Purdue Pharma today announced that, following completion of Phase II studies, they have exercised their option and taken over full responsibility from Laboratorios Esteve for the clinical, regulatory and commercial development of a potential first-in-class sigma-1 antagonist (AS1 o MR309/E-52862). In June 2012, Esteve has moved its Center for Drug Discovery and Preclinical Development to the Barcelona Science Park (PCB) in an attempt to shorten development time and speed up the arrival to market of innovative new drugs. 

 

Esteve and the Barcelona Science Park strengthen their collaboration for the discovery of new analgesic agents Blog Post

Esteve and the Barcelona Science Park (PCB) have decided to strengthen their collaboration in the field of Discovery of new molecular compounds with analgesic properties through the creation of the ESTEVE-PCB Joint Research Unit. This Unit based at the PCB, at the University of Barcelona campus, is intended to potentiate synergies in the field of chronic pain, a medical need that is not yet fully covered by currently available therapies.     

 

Mind the Byte launches six new software to accelerate drug discovery Blog Post

In line with the ground-breaking pay-per-use philosophy, Mind the Byte has launched six new programs for computational drug design on their SaaS platform (Software as a Service), which the company has been marketing since 2011. The new software expands the services currently on offer and helps cut drug-development time and costs up to 30% for companies and researchers. The products were launched at prices that adapt to the needs of each user.

 

Discovery of a fundamental limit to the evolution of the genetic code Blog Post

Headed by ICREA researcher Lluís Ribas de Pouplana at the Institute for Research in Biomedicine (IRB Barcelona) and in collaboration with Fyodor A. Kondrashov, at the Centre for Genomic Regulation (CRG) and Modesto Orozco, from IRB Barcelona, the team of scientists has demonstrated that the genetic code evolved to include a maximum of 20 amino acids and that it was unable to grow further because of a functional limitation of transfer RNAs—the molecules that serve as interpreters between the language of genes and that of proteins. This halt in the increase in the complexity of life happened more than 3,000 million years ago, before the separate evolution of bacteria, eukaryotes and archaebacteria, as all organisms use the same code to produce proteins from genetic information.

 

Eugin grows its business to 14,000 treatments per year Blog Post

Eugin Clinic performed 13,885 assisted reproduction treatments in 2015, which places it as one of the European leaders in the sector. The international centre, which has its basic research laboratory at the Barcelona Science Park (PCB), performs 10% of the treatments by means of egg donation from all over Europe and their success rates, which are verified by the prestigious German certification agency, TÜV, confirm that 9 in10 women achieve pregnancy. Eugin is also undertaking a large number of scientific projects with leading research centres and six European universities, including the University of Barcelona (UB).

 

A bridge towards new business opportunities in Korea Blog Post

Pharmaphenix –based at the Barcelona Science Park specializing in business development in emergent markets in Latin American and Korea with increasing activity in the Spanish market– has taken part one more year at BIO Korea, the largest partnering conference of the biotech, pharmaceutical and innovation sector in Asia. For three days, the pharmaceutical consultancy firm- with headquarters in Barcelona and in Seoul, South Korea– has intensified its contacts with key actors of the national bio-health sector to consolidate itself as a benchmark partner in the region. 

 

Mind the Byte and Sequentia take part in a trade mission in Massachusetts Blog Post

Mind the Byte and Sequentia Biotech, both based at the Barcelona Science Park (PCB), have been two of the 10 Catalan companies that participated last week in a trade mission in the state of Massachusetts (US) to search for business opportunities in the fields of digital health and big data applied to life sciences. The trade mission was organized by the Government of Catalonia through ACCIÓ, the agency for business competitiveness, and Biocat coinciding with Bio-IT World Conference & Expo, one of the largest and most important events in the US in the field of ICTs in the health sector.  

 

Intelligent Pharma receives the TECNIO accreditation Blog Post

Yesterday, 7 April, the Government of Catalonia presented the new TECNIO accreditation in an event led by the Minister of Business and Knowledge, Jordi Baiget, that brought together nearly 300 people from the Catalan scientific and technological community at the Mediapro building. The seal identifies in a first phase 54 entities that offer the most innovative technologies to help business create products, processes or services. Intelligent Pharma, specialized in computational chemistry services for the pharmaceutical and biotechnological industry, based at the Parc Científic de Barcelona, was one of the companies honored to have received this accreditation.